TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.

November 9, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has selected 12 late-breaking clinical trials and 16 first report Investigations that are guaranteed to impact patient care and future directions in cardiovascular technologies. 
 
Monday, October 30 - Main Arena I
Late-Breaking Clinical Trials 1

Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and presentation of results from the REVEAL outcomes study of anacetrapib, Merck’s investigational cholesteryl ester transfer protein (CETP) inhibitor. In the study of 30,449 patients with atherosclerotic vascular disease receiving LDL-C lowering treatment with atorvastatin, anacetrapib significantly reduced the risk of major coronary events (composite of coronary death, myocardial infarction or coronary revascularization) by 9 percent relative to placebo (10.8% vs. 11.8%, respectively; P=0.004). The safety of anacetrapib was generally consistent with data from earlier trials of the drug. However, a sub-study also showed that anacetrapib accumulates in adipose tissue with prolonged dosing.

September 11, 2017 — Veniti Inc. announced that Boston Scientific will distribute the Vici Venous Stent under a limited global distribution agreement. The terms of the agreement and specific regions and countries involved were not disclosed.

Cardiologists Conference

September 11, 2017 — Researchers have led a retrospective single-center study examining simple hemodynamic parameters obtained at the time of cardiac catheterization to predict in-hospital mortality following ST-elevation myocardial infarction (STEMI). Current 30-day mortality rates for primary percutaneous coronary intervention (PCI) patients with STEMI range from 2.5 to 10 percent, and 10.5 to 24 percent of those patients require mechanical hemodynamic support.

A cardiovascular service line manager reader of DAIC recently e-mailed me and asked if I had a list of the top technologies that will likely change cardiology in the next few years. He wanted this information for a capital improvement planning for the next decade. I did not have this compilation handy, so I wrote the following list of 17 technology trends I feel will change how cardiology is practiced over the next 10 years, based on my industry observations. These items are not listed in any particular order of importance:

September 8, 2017 — ClearFlow Inc. announced recently that positive clinical trial results were presented at the International Coronary Congress (ICC) 2017 annual meeting, Aug. 18-20 in New York City. The findings were presented by the study principal investigator Yvon Baribeau, M.D., FACS, of Catholic Medical Center in Manchester, N.H., in a presentation titled “Active Clearance of Chest Drains Reduces Retained Blood and ICU Resources after Off-Pump Coronary Artery Bypass Surgery.”

Abbott will end sales of the Absorb bioresorbable stent scaffold, pulling it off the market September 14, 2017.

September 8, 2017 — Abbott Vascular has announced it will end commercial sales of its Absorb bioresorbable vascular scaffold as of Sept. 14, 2017. The company said low sales of the bioabsorbable stent led to the decision to stop offering the product.  

September 7, 2017 — Sapheneia and Scannerside received U.S. Food and Drug Administration (FDA) 510(k) clearance to market their XR-29 DoseCheck solution.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now